CDSCO Panel gives nod for FDC Tamsulosin + Solifenacin

Fixed dose combination (FDC): The combination of Tamsulosin and Solifenacin relieves the symptoms of benign prostatic hyperplasia.

186
CDSCO Panel
CDSCO Panel

Last Updated on December 8, 2022 by The Health Master

New Delhi: Pharmaceutical major, Cipla has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to manufacture and market the fixed-dose combination (FDC) drug Solifenacin Succinate 6mg plus Tamsulosin HCl 0.4mg

However, this approval is conditional on the firm conducting the Phase IV clinical trial study and submitting the study protocol to CDSCO for review by the SEC within three months of approval.

This came after the firm presented its proposal along with a bioequivalence (BE) study report conducted for export purposes as well as justification for the Phase III clinical trial waiver.

In addition, the firm notified that the product is already approved in countries like Europe and the UK.

Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.

Tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used to treat benign prostatic hyperplasia, ureteral stones, prostatitis, and female voiding dysfunction.

The combination of Tamsulosin and Solifenacin relieves the symptoms of benign prostatic hyperplasia.

They work by relaxing the muscle around the bladder exit and prostate gland so urine is passed more easily. This prevents frequent, urgent, or uncontrolled urination.

At the recent SEC meeting for Reproductive and Urology held on November 30, the expert panel reviewed the proposal along with the BE study report conducted for export purposes as well as the justification for the Phase III clinical trial study waiver of the FDC drug Solifenacin Succinate 6mg plus Tamsulosin HCl 0.4mg.

Following extensive deliberation, the committee recommended that permission be granted to manufacture and market the FDC drug Solifenacin Succinate 6 mg plus Tamsulosin HCl 0.4 mg, subject to the completion of the Phase IV clinical trial study.

The committee also asked the firm to submit the study protocol within three months from the date of approval to CDSCO for further evaluation.

CDSCO panel gives nod for Esomeprazole Dual Release Gastro resistant Tablets

CDSCO gives approval for this Anti-diabetic drug

CDSCO gives nod to Dapagliflozin Tablets

CDSCO approves 4 more Medical Device Testing Labs (MDTL)

DCGI gives nod to Intranasal C-19 booster dose

IPC alert: About Norfloxacin induced skin hyperpigmentation

NPPA releases 4th list of draft ceiling prices for 15 formulations

J&J baby powder sample fails quality test: FDA latest lab report

NPPA releases 3rd list with draft ceiling prices for 43 formulations

Drug recall: Sodium Bicarbonate Injection recalled due to this reason

USFDA-Gujarat FDCA to meet to discuss GMP compliance, capacity building

CDSCO panel gives nod for Esomeprazole Dual Release Gastro resistant tablets

Drug recall: Dr. Reddy’s, Sun Pharma recall these drugs due to this reason

IPC releases amendment list for IP 2022, details here

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news